Aqilion appoints Scientific Advisory Board
Aqilion today announces the formation of a Scientific Advisory Board with three key appointments: Dr. Luc Michel Biedermann, Professor Albert J Bredenoord and Professor Evan S. Dellon. The Scientific Advisory Board will work closely with Aqilion’s management in the development of the company's Regulus program in preparation for planning Phase 2 trials in patients with the inflammatory disease Eosinophilic Esophagitis (EoE).Within the Regulus program, Aqilion is developing the drug candidate AQ280, a selective JAK-1 inhibitor, as a potential oral treatment for EoE, an allergic disease of
